Archive: December 16 2020

Find relevant news articles from other European projects, below:


Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:

Immunotherapy Web Featured Images 61

Subanalysis of KarMMA study (idecabtagene vicleucel in MM) and updated results o...

In an interview with Targeted Oncology, Jesus G. Berdeja, MD, discussed a subanalysis of the KarMMA study and updated results from CARTITUDE-1, which provide insights on the use CAR T-cell therapy in heavily pretreated patients with multiple myeloma, including the elderly and frail.

Visit website
Immunotherapy Web Featured Images 66

Interim data from phase II Zuma-5 study (axicabtagene ciloleucel in FL and MZL) ...

Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR T-cell therapy, leads to a high rate of strong and sustained responses in adults with relapsed or refractory (resistant) follicular lymphoma, known as FL, or marginal zone lymphoma, called MZL, who received at least two prior therapy lines, according to interim data from a Phase 2 trial.

Visit website
Immunotherapy Web Featured Images 62

Interim data of D-ALBA study: blinatumomab and TKI therapy as consolidation and ...

Prof Geyer speaks to ecancer about an ongoing phase II study which has been presented at this year’s ASH virtual conference regarding blinatumomab and concurrent oral tyrosine kinase inhibitor therapy as consolidation and maintenance therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia following chemotherapy-sparing induction.

Visit website
Immunotherapy Web Featured Images 64

ASH 2020 | Updates at ASH 2020 on bispecific antibodies in MM

  Dec 16 2020 Tagged MM, mAbs

Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses the progress being made in the field of bispecific antibodies in multiple myeloma.

Visit website
Immunotherapy Web Featured Images 63

ASH 2020 | IMGN632: a novel CD123-targeted antibody-drug conjugate for R/R BPDC

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a trial (NCT03386513) of IMGN632, a novel antibody-drug conjugate (ADC), in relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), a setting with poor outcomes and minimal treatment options.

Visit website